Goralatide (Ac-SDKP)10mg
Goralatide (Ac-SDKP) Canada — 10 mg Lyophilized Vials
Thymosin β4 Fragment Peptide
TB-500 is a synthetic peptide corresponding to an actin-binding region of thymosin β4. The designation "ACDSK TB500" references the N-terminal acetylated sequence commonly used to identify material of this type. It is supplied for laboratory research only.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
TB-500 is a synthetic peptide corresponding to an actin-binding region of thymosin β4. The designation "ACDSK TB500" references the N-terminal acetylated sequence commonly used to identify material of this type. It is supplied for laboratory research only.
In scientific literature, TB-500 appears in preclinical tissue repair models, in materials science work pairing the peptide with hydrogel delivery systems, and in analytical chemistry publications developing detection methods for small peptides. The published record for this specific compound is limited, and several papers address its identity and labelling rather than its biology.
Third-party tested for purity, ID, quantity.
TB-500 is described in the literature as a short fragment derived from thymosin β4, a β-thymosin protein characterised through its binding of monomeric actin and its role in cytoskeletal dynamics. Research discussions of the fragment generally frame its activity in terms of actin sequestration and associated cell migration processes, although mechanistic characterisation of the synthetic fragment itself, as distinct from full-length thymosin β4, remains incomplete in the published record.
Experimental endpoints evaluated to date include corneal injury repair in a hydrogel-delivery model, Achilles tendon healing assessed by histopathological and biomechanical measures in rats, and neuroinflammation and neurite morphology in cell models and a transgenic mouse model of Alzheimer's disease using thymosin β4-derived peptides. Separately, analytical studies have examined TB-500 as a target analyte in doping-control screening methods and have characterised the actual composition of products marketed under the TB500 and TB1000 names.
TB-500 originates from research on thymosin β4, an actin-binding peptide studied for its involvement in cytoskeletal regulation. The specific circumstances under which the shortened synthetic fragment was first prepared and named are not well documented in the peer-reviewed literature, and the candidate record does not establish a clear development history.
The compound entered the analytical literature in the 2010s, when doping-control laboratories developed screening methods capable of detecting small peptides including TB-500. Later work specifically examined products sold as TB500 and TB1000, reporting on misbranding and adulteration in materials circulating outside regulated supply chains. Recent reviews in orthopaedics and sports medicine discuss the peptide as an example of an unapproved compound, noting the gap between its circulation and the available evidence base.
TB-500 appears in three distinct research frameworks. The first is preclinical tissue repair: rodent tendon healing studies and a corneal injury model using an enzyme-triggered peptide hydrogel. The second is neurobiology, where thymosin β4-derived peptides have been assessed against neuroinflammatory and neurite endpoints in vitro and in a transgenic mouse model. The third is analytical and regulatory chemistry, covering mass spectrometry screening methods for small peptides and compositional analysis of commercially circulating material. Review literature in orthopaedics, sports medicine and gerontology discusses the peptide primarily in the context of limited evidence and unregulated distribution.
5 of the 5 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Lu 2025, Ou 2026, Mendias 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Lu 2025, Biçer 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Lu 2025, Ou 2026, Mendias 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Ou 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Jing 2022. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 6 primary papers published between 2022 and 2026 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Goralatide (Ac-SDKP) is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Goralatide (Ac-SDKP), set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Goralatide (Ac-SDKP) is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under actin-binding peptide and cytoskeletal research, preclinical tendon and corneal repair models and peptide hydrogel delivery systems.
The 6 papers cited on this page, published between 2022 and 2026 (2 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Goralatide (Ac-SDKP) is per lot, not per product. The current 10mg lot ACSD-CA-26H-10 returned 99.938% purity, 12.26 mg measured, 122.6% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Goralatide (Ac-SDKP); it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Goralatide (Ac-SDKP), this lot measured 122.6% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for Goralatide (Ac-SDKP). Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Goralatide (Ac-SDKP) in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
Goralatide (Ac-SDKP) is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains the labeled quantity of lyophilized TB-500. Independent third-party analysis verifies purity, identity, and net content per batch.
The vial contains only the lyophilized peptide. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs
PubMedEffects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
PubMedAlkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel
PubMedThymosin β4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro models and in vivo 5 × FAD mice: A potential therapy for memory improvement in Alzheimer's disease
PubMedSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
PubMedMulti-analyte screening of small peptides by alkaline pre-activated solid phase extraction coupled with liquid chromatography-high resolution mass spectrometry in doping controls
PubMedRelated
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
